论文部分内容阅读
目的探讨罗格列酮对OLETF鼠股骨骨密度(BMD)及骨形成蛋白-2(BMP-2)表达的影响及机制。方法 OLETF雄性大鼠20只,定期口服葡萄糖耐量试验(OGTT)监测血糖。喂养至30 w时,共有成模的2型糖尿病(T2DM)OLETF大鼠12只,随机分为罗格列酮组和模型组(每组6只),LETO鼠8只作为对照组,各组均给药12 w。双能X-线骨密度仪(DEXA)测定股骨BMD。股骨经固定、脱钙后,制成切片,光镜观察其病理变化,并运用免疫组化方法对BMP-2表达情况进行检测,应用图像分析软件进行分析。结果与模型组相比,罗格列酮组股骨BMD及成骨细胞BMP-2阳性表达强度明显降低(P<0.01),对照组BMD及BMP-2阳性表达强度明显升高(P<0.01)。结论 2型糖尿病本身可干扰成骨细胞功能和活性,而罗格列酮对自发肥胖型T2DM大鼠股骨有加重损害作用。
Objective To investigate the effect and mechanism of rosiglitazone on bone mineral density (BMD) and bone morphogenetic protein-2 (BMP-2) expression in OLETF mice. Methods Twenty OLOL male rats were randomly divided into two groups. The blood glucose level was monitored by OGTT. Twelve OLETF rats with established type 2 diabetes mellitus (T2DM) were fed with rosiglitazone and model groups (6 rats in each group), and 8 LETO rats served as control group All were given 12 w. Dual-energy X-ray absorptiometry (DEXA) was used to determine femoral BMD. The femur was fixed, decalcified and then made into slices. The pathological changes of the femur were observed with light microscope. The expression of BMP-2 was detected by immunohistochemical method and analyzed by image analysis software. Results Compared with model group, the positive expression of BMP-2 in femoral BMD and osteoblast was significantly decreased in rosiglitazone group (P <0.01), and the positive expression of BMD and BMP-2 in rosiglitazone group was significantly increased (P <0.01) . Conclusion Type 2 diabetes may interfere with osteoblast function and activity, while rosiglitazone may aggravate the femur of spontaneously obese T2DM rats.